Efficacy of SGLT2 Inhibitors in Patients With Diabetes and Nonobstructive Hypertrophic Cardiomyopathy

Subramanian, Muthiah; Sravani, Vucha; Krishna, Sanga Pavan; Bijjam, Swapnakala; Sunehra, Chandramukhi; Yalagudri, Sachin; Saggu, Daljeet Kaur; Narasimhan, Calambur

doi:10.1016/j.amjcard.2022.10.054

Cited by 9 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are initial reports on the positive effects of SGLT2 inhibitors in this patient group. In a prospective study involving HCM patients taking these medications for 6 months, there was a significant improvement in LV diastolic function parameters, an increase in the 6-minute walking test distance, and a reduction in N-terminal pro-B-type natriuretic peptide levels compared to the placebo group [8].…”

Section: Discussionmentioning

confidence: 97%

HFpEF mimics: hypertrophic cardiomyopathy in light of the 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure with Preserved Ejection Fraction

Maj,

Major,

Lelonek

2023

Folia Cardiologica

View full text Add to dashboard Cite

Hypertrophic cardiomyopathy is a genetic condition which leads to myocardial hypertrophy. Main cause of death in a group of patients with this disease is sudden cardiac death. In this article we present a diagnostic path which is consistent with the American College of Cardiology Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction diagnostic path. This led to diagnosis of hypertrophic cardiomyopathy and classifying it to the newly established amongst heart failure with preserved ejection fraction group -HFpEF mimics.

show abstract

Section: Discussionmentioning

confidence: 97%

HFpEF mimics: hypertrophic cardiomyopathy in light of the 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure with Preserved Ejection Fraction

Maj,

Major,

Lelonek

2023

Folia Cardiologica

View full text Add to dashboard Cite

show abstract

“…Показник градієнта на вихідному тракті в стані спокою у хворих до тесту становив 11,2 (10,1-19), після фармакологічної проби показник достовірно підвищився -12,45 (8,9-17) (р = 0,042). Показник градієнта на висоті проби Вальсальви до приймання препарату був 15 (11-29), після приймання емпагліфлозину показник також підвищився -15,45 (10,, але не досягнув рівня достовірності (р = 0,29) (рисунок 1).…”

Section: ехокардіографіяunclassified

“…Дані літератури щодо застосування іНЗКТГ2 у хворих з ГКМП обмежені. У дослідженні Subramanian et al (2023) [10] іНЗКТГ2 емпагліфлозин був застосований у хворих з необструктивною формою ГКМП. Після 6 місяців лікування емпагліфлозином у хворих відзначалося покращення показників діастолічної функції лівого шлуночка, покращення функціонального класу СН за NYHA на основі тесту 6-хвилинної ходьби, а також знижувався показник NT-proBNP (натрійуретичний гормон типу N-кінцевий поліпептид) та маси міокарда лівого шлуночка.…”

Section: ехокардіографіяunclassified

“…Проте з двох досліджень, що присвячені вивченню ефективності іНЗКТГ2 при СН зі збереженою фракцією викиду, у дослідженні дапагліфлозину ГКМП була критерієм виключення [8], а в дослідженні емпагліфлозину критерієм виключення була обструктивна форма захворювання [9]. Аналіз нечисленних публікацій щодо субаналізу групи з ГКМП у дослідженні емпагліфлозину свідчить про позитивний вплив на перебіг СН та зниження натрійуретичних пептидів у хворих з ГКМП [10].…”

unclassified

See 1 more Smart Citation

Individual Approach to Prescribing Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Hypertrophic Cardiomyopathy

Tseluyko,

Butko,

Kinoshenko

et al. 2024

ujcvs

View full text Add to dashboard Cite

Hypertrophic cardiomyopathy (HCM) is a common hereditary disease of the myocardium. Sodium-glucose co-transporter 2 inhibitors are recognized as first-line drugs for the treatment of heart failure, but at the moment there is little known about their use in HCM. The aim. To assess the possibility of using an acute test with empagliflozin in patients with HCM with echocardiographic assessment of left ventricular outflow tract (LVOT) obstruction. Materials and methods. Twenty-six non-obstructive HCM patients were examined. All the patients underwent an acute test with sodium-glucose co-transporter 2 inhibitor using 10 mg of empagliflozin and echocardiographic examination before and 3 hours after administration. Twenty-four patients were included in the further analysis (2 patients were excluded due to arrhythmia). The patients were divided into two groups: group 1 included subjects with an increase in LVOT pressure after empagliflozin (12 patients), group 2 included those without an increase in the gradient (12 patients). Results. During the acute test, an increase in LVOT gradient occurred in 12 patients, and in 6 patients the gradient increased significantly and reached more than 30 mm Hg. The indicator at rest in patients before the test was 11.2 (10.1-19), after the test it was 12.45 (8.9-17) mm Hg (p = 0.042). The indicator at the height of the Valsalva test also increased from 15 (11-29) to 15.45 (10.4-33) mm Hg (p=0.29). Comparative analysis of clinical and echocardiographic data did not show significant difference between the groups. Conclusions. In some patients with HCM without signs of overt or latent obstruction at the baseline, a significant increase in LVOT pressure was noted after acute test with empagliflozin. Conducting an acute test in patients with HCM is appropriate to determine the possibility of the development of LVOT obstruction while taking the drug.

show abstract

“… 3 In a recent small open-label study, SGLT2i were noted to improve symptoms in diabetic HCM patients. 5 However, there remains a paucity of data on SGLT2i on safety and impact on clinical outcomes in HCM.…”

mentioning

confidence: 99%

Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Mortality in Hypertrophic Cardiomyopathy

Aglan,

Fath,

Eldaly

et al. 2024

JACC: Advances

View full text Add to dashboard Cite

Efficacy of SGLT2 Inhibitors in Patients With Diabetes and Nonobstructive Hypertrophic Cardiomyopathy

Cited by 9 publications

References 23 publications

HFpEF mimics: hypertrophic cardiomyopathy in light of the 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure with Preserved Ejection Fraction

HFpEF mimics: hypertrophic cardiomyopathy in light of the 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure with Preserved Ejection Fraction

Individual Approach to Prescribing Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Hypertrophic Cardiomyopathy

Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Mortality in Hypertrophic Cardiomyopathy

Contact Info

Product

Resources

About